<SEC-DOCUMENT>0001209191-24-001436.txt : 20240111
<SEC-HEADER>0001209191-24-001436.hdr.sgml : 20240111
<ACCEPTANCE-DATETIME>20240111145518
ACCESSION NUMBER:		0001209191-24-001436
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240101
FILED AS OF DATE:		20240111
DATE AS OF CHANGE:		20240111

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Arjona Ferreira Juan Camilo
		CENTRAL INDEX KEY:			0001714080
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40235
		FILM NUMBER:		24529035

	MAIL ADDRESS:	
		STREET 1:		C/O MYOVANT SCIENCES INC.
		STREET 2:		2000 SIERRA POINT PARKWAY, 9TH FLOOR
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER NAME:	
		FORMER CONFORMED NAME:	Ferreira Juan Camilo Arjona
		DATE OF NAME CHANGE:	20170807

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Organon & Co.
		CENTRAL INDEX KEY:			0001821825
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464838035
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		30 HUDSON STREET
		STREET 2:		FL 33
		CITY:			JERSEY CITY
		STATE:			NJ
		ZIP:			07302
		BUSINESS PHONE:		551-430-6000

	MAIL ADDRESS:	
		STREET 1:		30 HUDSON STREET
		STREET 2:		FL 33
		CITY:			JERSEY CITY
		STATE:			NJ
		ZIP:			07302
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2024-01-01</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001821825</issuerCik>
        <issuerName>Organon &amp; Co.</issuerName>
        <issuerTradingSymbol>OGN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001714080</rptOwnerCik>
            <rptOwnerName>Arjona Ferreira Juan Camilo</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ORGANON &amp;CO.</rptOwnerStreet1>
            <rptOwnerStreet2>30 HUDSON STREET, FLOOR 33</rptOwnerStreet2>
            <rptOwnerCity>JERSEY CITY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07302</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Head of R&amp;D &amp; CMO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>13.355</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Restricted Stock Units</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2024-08-11</value>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2026-08-11</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>34557</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Restricted Stock Units</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2024-11-07</value>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2026-11-07</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>19339</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">These restricted stock units vest and are distributed as shares of Organon &amp; Co. common stock in three equal installments of 11,519 shares on each of August 11, 2024; August 11, 2025; and August 11, 2026.</footnote>
        <footnote id="F2">Each restricted stock unit represents a contingent right to receive one share of Organon common stock.</footnote>
        <footnote id="F3">These restricted stock units vest and are distributed as shares of Organon &amp; Co. common stock in three installments: 6,446 shares on November 7 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026.</footnote>
    </footnotes>

    <remarks>Exhibit 24-Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Tarnetta Jones, as Attorney-in-fact for Dr. Juan Camilo Arjona Ferreira</signatureName>
        <signatureDate>2024-01-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poa.txt
<DESCRIPTION>POA DOCUMENT
<TEXT>

Exhibit 24

POWER OF ATTORNEY


	The undersigned hereby constitutes and appoints each of Tarnetta V. Jones and
Faye. C. Brown, signing singly, the undersigned's true and lawful
attorney-in-fact, to:

(1)	 execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer or director of  Organon & Co. (the "Company"), Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act") and the rules thereunder;

(2)	do and perform any and all acts on behalf of the undersigned which may be
necessary or desirable to complete and execute any such Forms 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the United States Securities and Exchange Commission and any stock
exchange or similar authority; and

(3)     take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and condition as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or appropriate to be done in the exercise of any of the rights and
powers herein granted, as fully to all intents and purposes as the undersigned
might or could do if personally present, with full power of substitution or
ratification, hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to
be done by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney revokes all previous powers
of attorney with respect to the subject matter of this Power of Attorney.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 11th day of January, 2024.

/s/ Dr. Juan Camilo Arjona Ferreira



</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
